Navigation Links
Endometrial Ablation Offers Relief for Abnormally Heavy or Irregular Menstrual Bleeding
Date:9/21/2009

In the US, one in five women suffer from heavy periods or irregular bleeding. Not only does this condition lead to discomfort and embarrassment, it also negatively impacts daily routines. Irregular menstrual bleeding is called menorrhagia. Most women with menorrhagia don't know that heavy bleeding is not normal--it is a recognized medical condition for which they can seek treatment.

Phoenix, AZ (Vocus/PRWEB) September 20, 2009. In the US, one in five women suffer from heavy periods or irregular bleeding. Not only does this condition lead to discomfort and embarrassment, it also negatively impacts daily routines. Irregular menstrual bleeding is called menorrhagia. Most women with menorrhagia don't know that heavy bleeding is not normal--it is a recognized medical condition for which they can seek treatment.

Many women are embarrassed to seek medical attention for their heavy periods, believing that bleeding heavily for 4 to 5 days or changing their pad every hour is something they have to live with. Some women worry that their treatment options may be extreme or invasive. However, more options exist now that ever before for women suffering from abnormally heavy bleeding.

The most common treatment options include endometrial ablation, hormones, dilation and curettage (D&C), and hysterectomy. While a physician will recommend the proper treatment for the specific needs of the patient, studies have shown that hormones are minimally effective. Another option, D&C, can minimize symptoms, but the results are not long-term. Lastly, hysterectomy is a major surgery with significant risks and recovery time.

Endometrial ablation has emerged as an attractive alternative for the treatment of menorrhagia. This procedure treats the lining of the uterus to control or stop bleeding. It does not involve removal of the uterus and it does not affect a woman's hormone levels.

During the procedure a lighted viewing instrument (hysteroscope) and other instruments are used to destroy (ablate) the uterine lining, or endometrium.

Because endometrial ablation destroys a thin layer of the lining of the uterus, menstrual flow stops in many women. In some women, menstrual bleeding is only reduced to normal or lighter levels. If ablation does not control heavy bleeding, further treatment or surgery may be required.

The most common methods of ablation are thermal (by laser, radiofrequency, or heated saline,) Electricity (using a special scope and a loop or roller-ball electrode,) freezing or microwave.

Endometrial ablation is usually done in an outpatient facility or hospital and, depending on the method of ablation, usually takes only a short time to complete. The procedure may be done using a local or spinal anesthesia.

DoctorFinders.com helps to disseminate information regarding the treatments for menorraghia, including endometrial ablation, through its growing website. Thousands are logging on to not only learn of the latest advancements in the medical field, but to also find a physician or surgeon who is right for them.

Contact: Riley Horlacher
Company: DoctorFinders.com
Website: www.doctorfinders.com
Phone: (877) 619-7159

# # #

Read the full story at http://www.prweb.com/releases/womens_health/endometrial_ablation/prweb2917094.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Internal radiotherapy better than external for quality of life in endometrial cancer patients
2. Global view shows link between endometrial cancer and vitamin D status
3. Ovarian and Endometrial Cancer Patients Experience Improved Outcomes When Treated First by a Gynecologic Oncologist
4. Two Endometrial Cancer Treatments May Not Work
5. Ovary Removal May Not Be Needed in Endometrial Cancer
6. Study shows younger women with endometrial cancer can safely keep ovaries, avoid early menopause
7. Gene Mutation May Up Risks of Endometrial Cancer
8. Dream team targets key driver for breast, ovarian, endometrial cancers
9. New Data Support Use of Simple Test to Predict Endometrial Cancer Response to Chemotherapy
10. Obesity Greatly Raises Endometrial Cancer Risk
11. New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... Advice Media, the industry leader in digital ... companies in North America and has been included in the Inc. 5000 for the second ... honored to be included in the Inc. 5000 rankings for the second year in a ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... ... August 16, 2017 , ... The next Patient Care ... accepted. , Students who successfully complete the seven-week long Patient Care Academy are ... (CNA). The average starting salary for a CNA in Kalamazoo is $24,428.* , As ...
(Date:8/16/2017)... ... August 16, 2017 , ... Greenfield Advisors is honored to be named to ... second year in a row. The Inc. 5000 list honors private businesses across the ... on the list once is a great accomplishment, but for us to be included ...
(Date:8/16/2017)... , ... August 16, 2017 , ... Any Lab ... 5000. The company ranked #4429 on the newly released, 36th annual Inc. 5000 ... a unique look at the most successful companies within the American economy’s most dynamic ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
(Date:8/7/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO ... as president, effective Aug. 7, 2017. ... pursue other interests and will serve as president emeritus during ... served us in multiple leadership roles since he joined Diplomat ... and has provided decisive, strategic leadership which continues to benefit ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
Breaking Medicine Technology: